Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, TAVR | October 08, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date October 08, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,033.9103 |
Ending reported balance
After 2026-10-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-08 · Exercise / conversion · Acquired 619 · Balance 40,652.9103 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. Row 2 · 2026-10-08 · Sale · Disposed 619 · Balance 40,033.9103 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $72.68 · Expires 2027-05-06 | Direct | 3,095 |
Reported balance
After 2026-10-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-08 · Exercise / conversion · Disposed 619 · Balance 3,095 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2025 Filed Nov 10, 2025 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,020 | $82.55 | $84,196.00 |
DisclosureSEC source: 0001225208-25-009066 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,001.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $82.27 to $82.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2025 Filed Nov 10, 2025 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 1,020 | $59.26 | $60,441.83 |
DisclosureSEC source: 0001225208-25-009066 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,021.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
| July 28, 2025 Filed Jul 28, 2025 22:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,114 | $79.46 | $326,900.50 |
DisclosureSEC source: 0001225208-25-006815 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,001.9103 F1 · price: This transaction was executed in multiple trades at prices ranging from $79.4500 to $79.4701. The price reported above reflects the weighted average sale price. The reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2025 Filed Jul 7, 2025 21:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 333 | $76.79 | $25,571.07 |
DisclosureSEC source: 0001225208-25-006588 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,115.9103 Read SEC document |
| May 11, 2025 Filed May 12, 2025 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 271 | $73.68 | $19,967.28 |
DisclosureSEC source: 0001225208-25-004997 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,345.1066 Read SEC document |
| May 09, 2025 Filed May 9, 2025 23:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 330 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-004947 · doc4.xml · derivative · entry 6 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 330 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2025 Filed May 9, 2025 23:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 330 | $74.42 | $24,559.66 |
DisclosureSEC source: 0001225208-25-004947 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,616.1066 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.135 to $74.735. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2025 Filed May 9, 2025 23:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 330 | $45.28 | $14,941.31 |
DisclosureSEC source: 0001225208-25-004947 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,946.1066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 4,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004947 · doc4.xml · derivative · entry 5 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,225 Underlying: Common Stock · 4,225 shares Expires not disclosed F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 21,500 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004947 · doc4.xml · derivative · entry 4 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2032-05-07 F4 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 4,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004947 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,616.1066 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2025 Filed May 5, 2025 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 247 | $75.65 | $18,685.55 |
DisclosureSEC source: 0001225208-25-004769 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,391.1066 Read SEC document |
| May 03, 2025 Filed May 5, 2025 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 225 | $75.65 | $17,021.25 |
DisclosureSEC source: 0001225208-25-004769 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,638.1066 Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 21:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 300 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-004176 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330 Underlying: Common Stock · 300 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 21:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $70.61 | $21,183.00 |
DisclosureSEC source: 0001225208-25-004176 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,863.1066 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 21:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 300 | $45.28 | $13,583.01 |
DisclosureSEC source: 0001225208-25-004176 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,163.1066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| March 10, 2025 Filed Mar 10, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 400 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-003194 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630 Underlying: Common Stock · 400 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2025 Filed Mar 10, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 400 | $69.48 | $27,792.00 |
DisclosureSEC source: 0001225208-25-003194 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,588.0651 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| March 10, 2025 Filed Mar 10, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 400 | $45.28 | $18,110.68 |
DisclosureSEC source: 0001225208-25-003194 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,988.0651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 222 | $76.19 | $16,914.18 |
DisclosureSEC source: 0001225208-25-001909 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,588.0651 Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 165 | $76.19 | $12,571.35 |
DisclosureSEC source: 0001225208-25-001909 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,810.0651 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 214 | $76.19 | $16,304.66 |
DisclosureSEC source: 0001225208-25-001909 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,975.0651 Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 500 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-001710 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,030 Underlying: Common Stock · 500 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 500 | $76.34 | $38,170.00 |
DisclosureSEC source: 0001225208-25-001710 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,189.0651 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 500 | $45.28 | $22,638.35 |
DisclosureSEC source: 0001225208-25-001710 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,689.0651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| January 16, 2025 Filed Jan 16, 2025 22:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 500 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-000685 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,530 Underlying: Common Stock · 500 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2025 Filed Jan 16, 2025 22:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 500 | $68.76 | $34,382.15 |
DisclosureSEC source: 0001225208-25-000685 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,189.0651 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.42 to $69.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2025 Filed Jan 16, 2025 22:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 500 | $45.28 | $22,638.35 |
DisclosureSEC source: 0001225208-25-000685 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,689.0651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| December 16, 2024 Filed Dec 16, 2024 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-24-010858 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,030 Underlying: Common Stock · 2,500 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2024 Filed Dec 16, 2024 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $74.08 | $185,195.75 |
DisclosureSEC source: 0001225208-24-010858 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,189.0651 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $73.715 to $74.335. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2024 Filed Dec 16, 2024 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,500 | $45.28 | $113,191.75 |
DisclosureSEC source: 0001225208-24-010858 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,689.0651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| July 11, 2024 Filed Jul 11, 2024 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 500 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-24-007400 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,530 Underlying: Common Stock · 500 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2024 Filed Jul 11, 2024 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 500 | $94.18 | $47,090.00 |
DisclosureSEC source: 0001225208-24-007400 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,189.0651 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| July 11, 2024 Filed Jul 11, 2024 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 500 | $45.28 | $22,638.35 |
DisclosureSEC source: 0001225208-24-007400 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,689.0651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| July 07, 2024 Filed Jul 8, 2024 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 410 | $92.32 | $37,851.20 |
DisclosureSEC source: 0001225208-24-007360 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,189.0651 Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 535 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-24-006926 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,030 Underlying: Common Stock · 535 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 535 | $90.00 | $48,150.00 |
DisclosureSEC source: 0001225208-24-006926 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,512.7443 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 535 | $45.28 | $24,223.03 |
DisclosureSEC source: 0001225208-24-006926 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,047.7443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 377 | $86.72 | $32,693.44 |
DisclosureSEC source: 0001225208-24-005983 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,512.7443 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · derivative · entry 8 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,900 Underlying: Common Stock · 2,900 shares Expires not disclosed F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 857 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · derivative · entry 7 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 857 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 15,500 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · derivative · entry 6 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-05-06 F3 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 857 | $85.60 | $73,359.20 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 5 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,889.7443 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 586 | $85.09 | $49,862.74 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 4 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,746.7443 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 857 | $36.75 | $31,494.75 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,332.7443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,475.7443 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 4,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005890 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,575.7443 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 291 | $85.25 | $24,807.75 |
DisclosureSEC source: 0001225208-24-005704 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,915.7443 Read SEC document |
| May 03, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 281 | $85.06 | $23,901.86 |
DisclosureSEC source: 0001225208-24-005704 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,206.7443 Read SEC document |
| April 09, 2024 Filed Apr 9, 2024 21:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 857 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-005020 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 857 Underlying: Common Stock · 857 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.